. Low expression of BEX4 and BEX5 was significantly associated with poor survival in patients with LUAD AJCC stage I and II. Kaplan-Meier survival curve of (A) BEX1, (B) BEX2, (C) BEX3, (D) BEX4 and (E) BEX5 high-and low-expression levels in patients with LUAD AJCC stage I and II. Survival curves were compared using the log rank test and P<0.05 was considered to indicate a statistically significant difference. BEX, brain-expressed X-linked; LUAD, lung adenocarcinoma; AJCC, American Joint Committee on Cancer. Figure S3 . Effect of BEX family expression levels on the survival time patients with LUAD AJCC stage III and IV. Kaplan-Meier survival curve of (A) BEX1, (B) BEX2, (C) BEX3, (D) BEX4 and (E) BEX5 high-and low-expression levels in patients with LUAD AJCC stage III and IV. Survival curves were compared using the log rank test and P<0.05 was considered to indicate a statistically significant difference. BEX, brain-expressed X-linked; LUAD, lung adenocarcinoma; AJCC, American Joint Committee on Cancer. Figure S4 . Analysis of mutations and copy number variations of the BEX family in patients with lung adenocarcinoma. The alteration frequency of (A) BEX1, (B) BEX2, (C) BEX3, (D) BEX4 and (E) BEX5 in different cohorts. BEX, brain-expressed X-linked; TCGA, The Cancer Genome Atlas. Figure S5 . Promoter methylation average value of BEX members between tumor tissues and normal tissues obtained from healthy controls from the MethHC database. (A) BEX1 promoter methylation was significantly upregulated in LUAD tissues. (B) BEX2 promoter methylation was similar in LUAD and normal tissues. (C) BEX3 promoter methylation was significantly upregulated in LUAD tissues. (D) BEX4 promoter methylation was similar in LUAD and normal tissues. (E) BEX5 promoter methylation was similar in LUAD and normal tissues. Analysis was performed using a two-tailed Wilcoxon test with a cut-off of P<0.05 with stringent false discovery rate control based on Bonferroni's method. BEX, brain-expressed X-linked; LUAD, lung adenocarcinoma. CATGTACGTTGCTATCCAGGC  CTCCTTAATGTCACGCACGAT  BEX1  ACAAGGATAGGCCCAGGAGTAA  TTCGAAAGCAGGGGTCTGTT  BEX2  TGGTACCTGTTCCCGGTGT  CCCCTCCGGGTCCCTTAC  BEX3  CCTTCGGTGCAGTCGTCAC  TGGTTGTTTTTCTGCTCCGCT  BEX4  GCGTCAAGAATCCGGAGGAG  TTGCCATGCTGACCGTAACT  BEX5 TGCAGTCTGGTAGTTGTCGC ACGCACTTAAAGACCTGCCA BEX, brain-expressed X-linked. Table SIII . Associations between BEX2 expression and patient clinical characteristics in The Cancer Genome Atlas lung adenocarcinoma cohort. 
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